SavedAdd your journal

Journals / Mikrobiyoloji Bülteni / 2009 / Cilt: 43 - Sayı: 1

In vitro activity of linezolid/ertapenem combination in resistant gram-positive bacteria

Dirençli gram-pozitif bakterilerde linezolid/ertapenem kombinasyonunun in vitro aktivitesi

BAYRI ERAÇ
HÜSEYİN TAŞLI
Şafak ERMERTCAN
FATMA FERİHA ÇİLLİ
MİNE HOŞGÖR LİMONCU
Pages
45–51
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although these results support the use of linezolid/ertapenem combination in infections caused by resistant gram-positive strains, further in vitro and in vivo studies are necessary.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The increasing prevalence of vancomycin-resistant enterococcus and methicillin-resistant staphylococcus infections has become a major therapeutic challenge and alternative therapy options are under consideration.
📊
Key Findings & Data:In vitro activity of linezolid/ertapenem combination at 1/2 x MIC (minimal Inhibitory Concentration), 1 x MIC and 4 x MIC concentrations for each of the isolates was determined by time-kill curve method.
💡
Conclusion & Impact:Although these results support the use of linezolid/ertapenem combination in infections caused by resistant gram-positive strains, further in vitro and in vivo studies are necessary.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Mikrobiyal duyarlılık testleri · Anti-enfektif ajanlar · Acetamides

Abstract

The increasing prevalence of vancomycin-resistant enterococcus and methicillin-resistant staphylococcus infections has become a major therapeutic challenge and alternative therapy options are under consideration. In the present study, we aimed to evaluate the in vitro antibacterial activity of linezolid combined with ertapenem against two vancomycin-resistant Enterococcus faecium (VREF), two methicillin-resistant Staphylococcus aureus (MRSA) and two methicillin-resistant Staphylococcus epidermidis (MRSE) strains isolated from clinical specimens. In vitro activity of linezolid/ertapenem combination at 1/2 x MIC (minimal Inhibitory Concentration), 1 x MIC and 4 x MIC concentrations for each of the isolates was determined by time-kill curve method. At 1 x MIC and 4 x MIC concentrations, additive effect was detected for MRSA (at 6 and 24 h) and VREF (at 6 h) strains. Synergism was observed between two antibiotics at 4 x MIC concentration against one of the MRSE strains at 6th hour. Additive effect was determined at 6th and 24th hours in this strain at 1 x MIC concentration. No synergism was present in the other MRSE strain but additive interaction was detected at 6 h (1/2 x MIC) and 24 h (1 x MIC). Although these results support the use of linezolid/ertapenem combination in infections caused by resistant gram-positive strains, further in vitro and in vivo studies are necessary.

Özet

Metisiline dirençli stafilokok ve vankomisine dirençli enterokok enfeksiyon sıklığının artışı tedavide önemli sorunlara yol açmakta olup, alternatif tedavi seçenekleri üzerinde durulmaktadır. Bu çalışmada; klinik örneklerden izole edilen 2 vankomisine dirençli Enterococcus faecium (VREF), 2 metisiline dirençli Staphylococcus aureus (MRSA) ve 2 metisiline dirençli Staphylococcus epidermidis (MRSE) suşu üzerine linezolid/ertapenem kombinasyonunun in vitro aktivitesi araştırılmıştır. Bu amaçla, linezolid/ertapenem kombinasyonunun 1/2 x MİK (minimum inhibitor konsantrasyonu), 1 x MİK ve 4 x MİK konsantrasyonları kullanılmış ve suşlar üzerindeki in vitro aktiviteler zamana bağlı öldürme eğrisi (time-kill) metodu ile belirlenmiştir. MRSA suşlarında 1 x MİK ile 4 x MİK değerlerinde 6. ve 24. saatlerde additif etki saptanırken, VREF suşlarında da aynı MİK değerlerinde 6. saatte additif etki gözlenmiştir. İncelenen MRSE suşlarından birinde, 4 x MİK değerinde 6. saatte 2 antibiyotik arasında sinerji belirlenmiş, bu suşta 1 x MİK değerinde 6. ve 24. saatlerde antibiyotikler additif etki göstermiştir. Diğer MRSE suşunda herhangi bir sinerji saptanmazken, 1/2 x MİK değerinde 6. saatte ve 1 x MİK değerinde 24. saatte additif etki görülmüştür. Bu sonuçlar, linezolid/ertapenem kombinasyonunun dirençli gram-pozitif suşların etken olduğu enfeksiyonların tedavisinde kullanılabileceği görüşünü desteklemekle birlikte, daha kapsamlı in vitro ve in vivo çalışmalara ihtiyaç vardır.

🔖

Cite This Article

ERAÇ, B., TAŞLI, H., ERMERTCAN, Ş., ÇİLLİ, F. F., LİMONCU, M. H. (2009). In vitro activity of linezolid/ertapenem combination in resistant gram-positive bacteria. Mikrobiyoloji Bülteni, Cilt: 43 - Sayı: 1, 45–51. https://ajindex.com/articles/298877

References (14)

  1. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control 2006; 34 (Suppl 1): 11-9
  2. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6
  3. Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48: 275-80
  4. Amyes SC. Enterococci and streptococci. Int J Antimicrob Agents 2007; 29 (Suppl 3): 43-52
  5. Donowitz GR. Oxazolidinones, p: 436. In: Mandell GL, Bennett JE, Dolin R (eds), Mandell,, Dolin and Bennett's Principles and Practice of Infectious Diseases. 2005, 6th ed. Churchill Livingstone, Philadelphia
  6. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57: 279-87
  7. Wilson P, Andrews JA, Charlesworth R, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 186-8
  8. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179
  9. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39: 1010-5
  10. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 (Suppl 2): ii11-21
  11. Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 418-20
  12. Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-64
  13. Jacqueline C, Navas D, Batard E, et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 45-51
  14. Jacqueline C, Caillon J, Grossi O, et al. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly